[Percutaneous treatment of mitral regurgitation by Mitraclip in the elderly]
- PMID: 30389097
- DOI: 10.1016/j.ancard.2018.10.007
[Percutaneous treatment of mitral regurgitation by Mitraclip in the elderly]
Abstract
Mitral regurgitation (MR) is the second most common form of valvular heart disease. It is classified as either primary (degenerative) or secondary (functional). Secondary MR is the consequence of myocardium disease. Primary MR from degenerative valve disease is due to a primary disruption of the mitral valve apparatus from either prolapsed or flail leaflets. It covers all aetiologies in which intrinsic lesions affect one or several components of the mitral valve apparatus. Gold-standard therapeutic management of severe primary MR is surgery usually to repair but sometime to replace the mitral valve. However patients considered to be at high-risk due to their age or the presence of comorbidities - accounting for 50% of all patients - are not eligible for surgery. Catheter-based interventions have been developed to correct MR percutaneously. The only such intervention which has been evaluated in organic MR is the edge-to-edge procedure using the MitraClip® (Abbott Vascular, Menlo Park, CA). MitraClip® offers an alternative to open surgical repair or replacement via a minimally invasive route and it was shown in the EVEREST II study that MitraClip® was safer than surgery even though it was less effective in reducing MR. A substantial number of patients are ineligible for mitral valve surgery because of prohibitive surgical risk. For those patients, MitraClip® may offer an alternative treatment option. Percutaneous edge-to-edge repair is the first percutaneous option accepted in the 2012 ESC guidelines: Percutaneous edge-to-edge procedure may be considered in patients with symptomatic severe primary MR who fulfill the echo criteria of eligibility, are judged inoperable or at high surgical risk by a 'heart team', and have a life expectancy greater than 1 year (recommendation class IIb, level of evidence C). Because of its frailty, MitraClip® in the elderly may be a good alternative to mitral surgery when indicated for primary or secondary MD.
Keywords: Elderly; Insuffisance mitrale; Mitraclip; Mitrale regurgitation; Percutaneous edge-to-edge repair; Réparation bord-à-bord; Âge.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Reduction of mitral valve regurgitation with Mitraclip® percutaneous system.Minerva Cardioangiol. 2010 Oct;58(5):589-98. Minerva Cardioangiol. 2010. PMID: 20948505
-
Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial.J Am Heart Assoc. 2023 Feb 21;12(4):e027504. doi: 10.1161/JAHA.122.027504. Epub 2023 Feb 8. J Am Heart Assoc. 2023. PMID: 36752231 Free PMC article. Clinical Trial.
-
Clinical outcomes of conventional surgery versus MitraClip® therapy for moderate to severe symptomatic mitral valve regurgitation in the elderly population: an institutional experience.BMC Cardiovasc Disord. 2017 Mar 20;17(1):85. doi: 10.1186/s12872-017-0523-4. BMC Cardiovasc Disord. 2017. PMID: 28320316 Free PMC article.
-
MitraClip Therapy for Mitral Regurgitation: Primary Mitral Regurgitation.Interv Cardiol Clin. 2016 Jan;5(1):71-82. doi: 10.1016/j.iccl.2015.08.006. Epub 2015 Oct 9. Interv Cardiol Clin. 2016. PMID: 27852483 Review.
-
Percutaneous Edge-to-Edge Transcatheter Mitral Valve Repair: Current Indications and Future Perspectives.Surg Technol Int. 2018 Jun 1;32:201-207. Surg Technol Int. 2018. PMID: 29791711 Review.
Cited by
-
Functional Mitral Regurgitation in the Transcatheter Era: Diagnostic and Therapeutic Pathways.J Pers Med. 2025 Aug 13;15(8):372. doi: 10.3390/jpm15080372. J Pers Med. 2025. PMID: 40863434 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical